Evidence map›Paper›PMID 36662890›Full record

ArticlePloS one2023

Identification of the properties of H5 influenza vaccine viruses with high hemagglutinin yields.

Tomoko Arita, Yasushi Suzuki, Noriko Shimasaki, Hirotaka Kobayashi, Hideki Hasegawa, Takato Odagiri, Masato Tashiro, Eri Nobusawa

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Tomoko AritaResearch Center for Influenza and Respiratory Viruses, National Institute of Infectious Diseases, Musashi-murayama, Tokyo, Japan.
Yasushi SuzukiResearch Center for Influenza and Respiratory Viruses, National Institute of Infectious Diseases, Musashi-murayama, Tokyo, Japan.
Noriko ShimasakiDepartment of Virology III, National Institute of Infectious Diseases, Musashi-murayama, Tokyo, Japan.
Hirotaka KobayashiDepartment of Pathology, National Institute of Infectious Diseases, Sinjuku, Tokyo, Japan.
Hideki HasegawaResearch Center for Influenza and Respiratory Viruses, National Institute of Infectious Diseases, Musashi-murayama, Tokyo, Japan.
Takato OdagiriResearch Center for Influenza and Respiratory Viruses, National Institute of Infectious Diseases, Musashi-murayama, Tokyo, Japan.
Masato TashiroResearch Center for Influenza and Respiratory Viruses, National Institute of Infectious Diseases, Musashi-murayama, Tokyo, Japan.
Eri NobusawaResearch Center for Influenza and Respiratory Viruses, National Institute of Infectious Diseases, Musashi-murayama, Tokyo, Japan.ORCID 0000-0003-0428-8606
National Institute of Infectious Diseases · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Manufactured influenza vaccines have to contain a defined amount of hemagglutinin (HA) antigen. Therefore, vaccine viruses with a high HA antigen yield (HAY) are preferable for manufacturing vaccines, particularly vaccines in response to a pandemic, when vaccines need to be rapidly produced. However, the viral properties associated with a high HAY have not yet been fully clarified. To identify the HAY-associated traits, we first propagated 26 H5 candidate vaccine viruses (CVVs) in eggs, which were previously developed based on genetic reassortment methods using master viruses, to determine their total protein yield (TPY), ratio of HA to total viral protein (%-HA content) and HAY. The results revealed that the HAY was correlated with the TPY but not with the %-HA content. We further found that altering the sequences of the 3' noncoding region of HA vRNA or replacing the master virus improved the HAYs and TPYs of the low-HAY CVVs to approximately double the values of the original CVVs but did not change the %-HA content, which a previous study suggested was associated with the HAY. Analyses based on real-time PCR assays and scanning electron microscopy revealed that the virus samples with an improved HAY contained more copies of the virus genome and viral particles than the original samples. The results suggest that an improvement in virus growth (i.e., an increase in the amount of viral particles) leads to an increase in the TPY and thus in the HAY, regardless of the %-HA content. The approximately twofold increase in the HAY shown in this study may not appear to represent a large improvement, but the impact will be significant given the millions of chicken eggs used to produce vaccines. These findings will be informative for developing high-HAY vaccine viruses.

Indexed as

Influenza VaccinesOrthomyxoviridaeAnimalsAntibodies, ViralChickensHemagglutinin Glycoproteins, Influenza VirusHemagglutininsAntibodies, ViralHemagglutinin Glycoproteins, Influenza VirusHemagglutininsInfluenza Vaccines

Identifiers

PMID36662890
PMCPMC9858889
OpenAlexW4317601320

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.